Novel drug achieves high objective response rate in heavily pretreated chronic lymphocytic leukemia
Cancer Network News highlights UC-led research
Cancer Network News highlighted research led by the University of Cincinnati Cancer Center's Zulfa Omer that found a novel drug was generally well tolerated and demonstrated early efficacy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Omer, MD, Cancer Center member and assistant professor in the Department of Internal Medicine in UC's College of Medicine, and colleagues shared data from the Phase 1 NX-5948-301 trial at the 2025 European Hematology Association Congress.
The trial is testing a novel drug called bexobrutideg that targets the BTK enzyme in a population of heavily pretreated patients with advanced CLL. The drug was found to be well tolerated at all dose levels.
At a median follow-up of 9 months, 80.9% of patients had an objective response, meaning a complete or partial response to the treatment. Out of 48 patients enrolled, seven patients had stable disease, meaning the cancer did not progress or decrease while being treated with the drug. Two patients experienced disease progression.
“Robust and deepening responses were observed [with bexobrutideg]. Responses were rapid, with a median time to first response of 1.87 months,” Omer and her study coauthors wrote in the poster presentation. “...Of 18 patients treated for more than 12 months, 17 remain on the study, [and] 1 patient is approaching 2.5 years on treatment.”
Read the Cancer Network News article.
Featured photo at top of CLL cells viewed under a microscope. Photo/jxfzsy/iStock Photo.
Related Stories
CCM welcomes new film and media scoring faculty member J.R. Paredes
May 20, 2026
UC College-Conservatory of Music Dean Pete Jutras has announced the appointment of J.R. Paredes as CCM's new Assistant Professor of Film and Media Scoring. His faculty appointment officially begins on Aug. 15, 2026. Paredes is a composer, music producer and audio post-production specialist whose work spans film, television and commercial music. His credits include original scores for feature films and series distributed on platforms such as Apple TV+ and Prime Video, as well as extensive work in sound design and mixing for film and media.
6 ways starting a GLP-1 medication could affect your emotions
May 20, 2026
When patients first start taking a glucagon-like peptide-1 (GLP-1) medication, they probably expect to feel full. But they might not anticipate how it can influence their emotions. The medications act on the stomach and the brain, said Malti Vij, MD, a University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine and a diplomate of the American Board of Obesity Medicine.